These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 31168408)

  • 1. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
    Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
    RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
    Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
    Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    Clin Rheumatol; 2017 Apr; 36(4):895-901. PubMed ID: 28271234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.
    Mease PJ; van der Heijde D; Karki C; Liu M; Park Y; Greenberg JD
    Rheumatol Ther; 2018 Dec; 5(2):537-550. PubMed ID: 30353387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Jacobsson L; Loft AG; Iannone F; Fagerli KM; Vencovsky J; Santos MJ; Möller B; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Cefle A; Eklund K; Codreanu C; Jones G; van der Sande M; Wallman JK; Sebastiani M; Michelsen B; Závada J; Nissen MJ; Sanchez-Piedra C; Tomšič M; Love TJ; Relas H; Mogosan C; Hetland ML; Østergaard M
    J Rheumatol; 2024 Apr; 51(4):378-389. PubMed ID: 38224992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.
    Mease PJ; Lesperance T; Liu M; Collier DH; Mason M; Deveikis S; Accortt NA
    J Rheumatol; 2017 Feb; 44(2):184-192. PubMed ID: 28089969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response.
    Mathew AJ; Hetland ML; Pedersen MP; Rasmussen SH; Glintborg B; Loft AG; Nissen MJ; Möller B; Rodrigues AM; Santos FP; Rotar Z; Tomšič M; Relas H; Peltomaa R; Gudbjornsson B; Löve TJ; Kocaer SB; Koken Avsar A; Midtbøll Ørnbjerg L; Østergaard M
    Scand J Rheumatol; 2024 Jul; 53(4):237-247. PubMed ID: 38771017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
    Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
    J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
    Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
    Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
    Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
    Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.
    Harrold LR; Stolshek BS; Rebello S; Collier DH; Mutebi A; Wade SW; Malley W; Greenberg JD; Etzel CJ
    J Rheumatol; 2018 Jan; 45(1):78-82. PubMed ID: 28966209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.
    Ogdie A; Palmer JL; Greenberg J; Curtis JR; Harrold LR; Solomon DH; Kavanaugh A; Kremer JM; Mease PJ
    J Rheumatol; 2019 May; 46(5):475-482. PubMed ID: 30647182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
    Vieira-Sousa E; Eusébio M; Ávila-Ribeiro P; Khmelinskii N; Cruz-Machado R; Rocha TM; Bernardes M; Santos-Faria D; Silva JL; Santos H; Miguel C; Carvalho P; Costa T; Duarte AC; Meirinhos T; Nero P; Fonseca JE; Santos MJ
    J Rheumatol; 2020 May; 47(5):690-700. PubMed ID: 31371659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
    Littlejohn G; Leadbetter J; Butcher BE; Feletar M; O'Sullivan C; Smith T; Witcombe D; Ng HY; Youssef P
    Clin Rheumatol; 2024 May; 43(5):1579-1589. PubMed ID: 38459357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
    Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
    Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
    Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Sharaf M; Theander E; Smolen JS
    Arthritis Res Ther; 2023 Jun; 25(1):109. PubMed ID: 37353788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.